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Introduction
T-helper (Th) 1, Th2, and Th17 cells mediate distinct acute graft-versus-host dis-
ease (GvHD) syndromes.1 In contrast, T-regulatory (Treg) cells prevent acute
GvHD2 and are associated with reduced clinical GvHD. T-helper subsets are prima-
rily driven by cross-regulatory transcription factors, namely: deficiency of Th1- and
Th17-driving transcription factors allows FoxP3+ Treg reconstitution and prevents
acute GvHD.3,4 However, transcription factor cross-regulation is less clear for chron-
ic GvHD, which is distinct from acute GvHD in part due to an autoimmune mech-
anism.5
Chronic GvHD is propagated by donor T cells that recognize host peptides pre-
sented by donor antigen-presenting cells. The pathological manifestations of chron-
ic GvHD therefore resemble those of autoimmunity.6-9 The mechanism by which
autoimmunity arises from alloimmunity remains unresolved.10 In animal models, a
decrease in Treg cells occurs along with an expansion of Th1 and Th17 cells,11
which leads to autoimmune pathology. During alloimmunity, donor T cells respond
to shared antigens, thereby resulting in repertoire skewing and recognition of non-
polymorphic antigens.12 There are no data indicating whether this process results in
prevention of the induction of Treg cells thereby resulting in long-term loss in
immune regulation. While animals models of chronic GvHD exist,13 there is a pauci-
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ABSTRACT
ty of data reproducing the break in T-cell regulation.
Hence, we utilized a chronic GvHD model11,12,14 that cap-
tures these two processes and allows understanding of the
specific regulatory signals that prevent immune tolerance
of alloreactive donor T cells and consequently cause
autoimmunity.
Chronic GvHD autoimmunity can be experimentally
dissected from acute GvHD by sequential allogeneic and
syngeneic T-cell transfer. In this secondary transfer
autoimmune chronic GvHD, Th1 and Th17 subsets pre-
dominate with a relative deficiency of Treg cells;11 a simi-
lar immune imbalance was also observed in a scleroder-
matous chronic GvHD model.15 However, the underlying
molecular mechanism by which such Treg insufficiency
occurs in chronic GvHD is still unknown but therapies
that enhance Treg numbers in patients with chronic
GvHD are promising.16 The existence of a Th1 component
in the pathogenesis of chronic GvHD diverges from initial
models that emphasized a Th2-dominant disease17 but is
not inconsistent with the current understanding of Th1-
mediated autoimmunity18 and knowledge that type I
immunity drives lethality in genetic Treg deficiency.19
Taken together, Th1-driving signaling molecules may
restrict peripheral Treg generation. 
We hypothesized that Th1-driving signals inhibit Treg
generation during chronic GvHD. Because interferon
(IFN)-γ signaling induces Tbet,20 which propagates Th1-
mediated inflammation, sequential deletion of IFN-γR fol-
lowed by Tbet may identify checkpoints that inhibit
peripheral Treg generation. We evaluated key Th1 tran-
scription factors, including STAT1 and STAT4, in modulat-
ing chronic GvHD.11 
Methods 
Mice
Female C57BL/6 (B6, H2Kb) and BALB/c (H2kd) mice 8- to 10-
weeks old were obtained from Frederick Cancer Research Facility.
Rag2−/−, Tbx21−/−, Ifnγ and Ifnγr−/− animals were from Jackson
Laboratories. B6.Tbx21−/−Foxp3-GFP mice were generated by
crossing B6.Tbx21−/− with B6.Foxp3GFP; B6.FoxP3GFP littermate
controls were simultaneously maintained. Mice were maintained
in a specific pathogen-free facility at the National Institutes of
Health. Drinking water was supplemented with ciprofloxacin
from day -1 to day +14 after bone marrow transplantation.
Experiments were carried out in accordance with National
Institutes of Health animal health and safety guidelines and
approved by the Animal Care and Use Committee, National
Cancer Institute, National Institutes of Health. 
Bone marrow transplant
Bone marrow experiments were performed as outlined in the
Online Supplementary Methods. 
Flow cytometry
On day 14 after allogeneic bone marrow transplantation,
splenocytes were stained with CD4 PE-Cy5 (H129.19), H2Kb PE
(AF6.88.5), CD3 FITC (145-2C11) and FoxP3 APC (FJK.16s;
eBioscience). After secondary transfer to Rag2−/− recipients, splenic
T cells were isolated and intracellular flow cytometry was per-
formed as outlined in the Online Supplementary Methods.  
Cytokine secretion assay after secondary transfer 
On the indicated day after secondary transfer into syngeneic
hosts, spleens were harvested and single cell suspensions were
obtained to test for autoreactivity, as outlined in the Online
Supplementary Methods.
Evaluation of in vivo tissue RNA genes after secondary
transfer 
On the indicated days, recipients’ skin tissue was evaluated for
chronic GvHD biomarkers as outlined in the Online Supplementary
Methods. 
Isolation of T cells from lamina propria lymphocytes
and skin 
Intraepithelial lymphocytes were removed and lamina propria
lymphocytes were separated.21 Lymphocytes were extracted from
the skin as previously described and outlined in the Online
Supplementary Methods.22
Chromatin immunoprecipitation 
Chromatin was immunoprecipitated as previously described
and outlined in the Online Supplementary Methods.23
Histopathology 
Tissue from Rag2−/− recipients (colon, skin) was fixed in 10%
(vol/vol) formyl saline and embedded in paraffin blocks. Tissue
sections were stained with eosin and hematoxylin and evaluated
by a pathologist (MAE).  Skin GvHD scores were either 0 (normal)
or 1 (acanthosis, hyperkeratosis); skin stages 2, 3, and 4, which
include mononuclear infiltrates and epidermal loss, were not
observed.  Intestinal GvHD was scored (0 to 4) according to degree
of mononuclear cell infiltration and crypt destruction (stage 1,
focal and mild; stage 2, diffuse and mild; stage 3, diffuse and mod-
erate; stage 4, diffuse and severe).
Statistics 
Kaplan-Maier survival analysis was performed and survival
curves were compared using log-rank testing. Statistical signifi-
cance was determined for normally distributed data using a two-
tailed Student t test or one-way analysis of variance (ANOVA) fol-
lowed by Dunn post-hoc tests. For statistical analysis of histology,
a Mann-Whitney-U test was performed. P values <0.05 were con-
sidered statistically significant. 
Results 
Type I signaling is important for autoimmune chronic
graft-versus-host disease
Experiments were designed to identify whether Th1
cells contributed to autoimmune chronic GvHD. A brief
schema of the chronic GvHD model is shown in Figure
1A. Wild-type (WT), IFN-γ-/-, IFNγR-/-, STAT1-/-, or STAT4-/-
CD4+ T cells were transferred into Rag2-/- recipients in the
post-alloreactive phase. Contradicting prior reports sug-
gesting that chronic GvHD primarily resembles a Th2
process,17,24 IFNγR-/- CD4+ T cells abrogated chronic GvHD
pathogenesis (Figure 1B); recipients had increased Treg-
cell numbers but no difference in IFNγ−producing T-effec-
tor cells; [#CD4+FoxP3+ (x103); mean±SEM, WT versus
IFNγ-/- versus IFNγR-/-; 3.35±1.5 versus 1.78±4.8 versus
37.8±11.4; #CD4+IFNγ+ (x103); mean±SEM, WT versus
IFNγ-/- versus IFNγR-/-; 46±19.7 versus 6±9 versus 83.7±20)
(Figure 1C-E). Recipients of STAT1-/- or STAT4-/- T cells had
increased Treg cells, decreased cytokine expression
[#CD4+FoxP3+ (x105); mean±SEM, WT versus STAT1-/- ver-
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Figure 1. Lack of Th1 signaling in T cells alleviates autoimmune graft-versus-host disease. Schematic representation of the experimental murine model for autoim-
mune chronic GvHD. (A) BALB/c mice were subjected to lethal total body irradiation (TBI) and then reconstituted with T-depleted (TD) bone marrow (BM) and CD4+
T cells from C57BL/6 (B6) mice. On day 14 after transplant, murine recipients were euthanized and B6.CD4+ T cells were isolated and adoptively transferred into
B6.Rag2-/- mice. The occurrence of autoimmune GvHD was monitored over a period of 60 days. Host BALB/c mice were subjected to TBI (950 cGy) and then recon-
stituted with allogeneic WT B6 TDBM (10M) and CD4+ T cells (2M). In certain cohorts, mice were reconstituted with BM and T cells deficient in IFN-γR, STAT1, STAT4,
or IFN-γ. On day 14 after allogeneic bone marrow transplantation, splenic CD4+ T cells from WT or KO recipients were isolated and adoptively transferred into B6
Rag2−/− mice. (B) Survival curves after secondary transfer of either WT or KO T cells (n=8-10 per cohort.  (C-H) Representative flow image and absolute numbers of
FoxP3+ CD4+T cells and IFNγ+ CD4+T cells in the WT and KO cohorts (n=10 per cohort).
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sus STAT4-/-; 0.64±0.13 versus 1.87±0.3 versus 3±0.8;
#CD4+IFNγ+ (x105); mean±SEM, WT versus STAT1-/- versus
STAT4-/-; 7.7±2.6 versus 0.2±0.2 versus 0.9±0.3) (Figure
1F,H), and reduced lethality (Figure 1B).
These results suggested that deficiency of Th1-cell signal-
ing (IFN-γR) or transcription factors (STAT1, STAT4) direct-
ly impaired chronic GvHD. However, such deficiencies
may have reduced chronic GvHD indirectly, namely, via
reduction in Th1 cytokines. To address this, we evaluated a
transplant cohort that received IFN-γ-deficient T cells: such
recipients had low IFN-γ and reduced Treg cells (Figure 1C-
E) and chronic GvHD lethality similar to that of WT con-
trols (Figure 1B). Recipients of IFNγR-/- T cells, even though
protected against chronic GvHD lethality, had similar IFN-γ
production to that of WT controls (Figure 1E). Recipients of
IFNγR-/-, STAT1-/-, and STAT4-/- T cells had similar numbers of
CD4+ T cells as the WT cohort [#CD4+ (x104); mean±SEM,
WT versus IFNγ-/- versus IFNγR-/-; 55.1±16.5 versus 50.8±14.3
versus 76.59±15.9; WT versus STAT1-/- versus STAT4-/-
133.8±18.4 versus 180.7±14.1 versus 129.4±14.6] (Online
Supplementary Figure S1A,C) and similar interleukin-17
(IL17) secretion [#CD4+IL17+ (x104); mean±SEM, WT versus
IFNγ-/- versus IFNγR-/- ; 25±10.6 versus 42.5±10.7 versus
31±7.6; WT versus STAT1-/- versus STAT4-/-; 0.51±0.005 versus
51.5±25 versus 75.9±54.4] (Online Supplementary Figure
S1B,D). These data indicate that the reduction in chronic
GvHD was primarily attributable to a deficiency in Th1 cell
signaling and Th1 cell transcription factors rather than a sec-
ondary deficiency in Th1 cytokines. 
Autoimmune graft-versus-host disease requires 
T-cell Tbx21
Increased Treg numbers in IFNγR-/- and STAT-/- cohorts
suggested an inhibitory mechanism by which Th1 signaling
molecules prevented peripheral Treg generation. Because an
increased number of Treg ceslls may be beneficial in
decreasing chronic GvHD,25-29 we characterized the mecha-
nism by which Treg cells were inhibited during chronic
GvHD. Experiments were performed with CD4+ T-effector
cells from Tbx21-/- mice (Tbet). Tbet is a master regulator of
Th1 cells; lack of Tbet results in Th1-cell deficiency. To
study the role of Tbet in chronic GvHD, we utilized Tbx21-
/- T cells.30 Consistent with published results,3 WT CD4+ T
cells caused acute GvHD in the alloreactive phase; in con-
trast, recipients of Tbx21−/− T cells were partially protected
against acute GvHD [WT: n=10/10 succumbed to acute
GvHD; knockout (KO): n=5/10 succumbed to acute
GvHD]. At the time of splenic T-cell harvest after allogeneic
bone marrow transplantation, the frequencies of Treg cells
in WT and Tbet-deficient recipients were similar (0.40%
versus 0.17%, respectively; P=NS). However, upon second-
ary transfer to Rag2−/− recipients, Tbx21−/− CD4+ T cells did
not mediate lethality (Figure 2A) or cause autoimmune
pathology (Figure 2B, representative result; Figure 2C,
pooled results). To evaluate potential cellular mechanisms,
subsequent cohorts were euthanized prior to lethality (day
60 after secondary transfer). Protection against autoimmune
GvHD was not associated with reduced numbers of CD4+
T cells [#CD4+ (x104); mean±SEM, WT versus Tbx21-/-,
17.2±0.5 versus 6.8±4.1] (Online Supplementary Figure S1E) or
Th17 effectors [#CD4+IL17+ (x103); mean±SEM, WT versus
Tbx21-/-, 2.5±1.3 versus 1.1±0.7] (Online Supplementary Figure
S1F) but was associated with reduced CD4+ IFN-γ+ cells
[#CD4+IFNγ+ (x104); mean±SEM, WT versus Tbx21-/-,
102.8±18.4 versus 27.1±4] (Figure 2D representative result,
2E pooled results). Next, we evaluated the number of Treg
cells in WT and Tbx21-/- cohorts. We reasoned that any sur-
vival advantage might be attributable to defective homing
of T cells to target tissues, thereby limiting GvHD-mediated
pathology.31 Homing defects can be directly attributed to
Tbet deficiency which is activated downstream of IFN-γR
signaling.20,32 However, contrary to this reasoning, we found
increased FoxP3+Treg cells in spleen [#CD4+FoxP3+ (x103);
mean±SEM, WT versus Tbx21-/-, 2.7±0.1 versus 18.8±4.6]
(Figure 2F), mesenteric lymph nodes [#CD4+FoxP3+ (x103);
mean±SEM, WT versus Tbx21-/-, 16.9±7.1 versus 169.9±52.8]
(Figure 2G), lamina propria [#CD4+FoxP3+ (x103);
mean±SEM, WT versus Tbx21-/-, 0.78±0.3 versus 1.72±0.2]
(Figure 2H), and skin [#CD4+FoxP3+ (x103); mean±SEM, WT
versus Tbx21-/-, 1.6±0.5 versus 3.8±0.7] (Figure 2I). STAT1
deficiency has been associated with enhanced Treg prolifer-
ation;33 however, a similar biology was not operational in
our model, as Tbet deficiency did not increase the Treg pro-
liferative phenotype [#CD4+Ki67+FoxP3+ (x103);
mean±SEM, WT versus Tbx21-/-, 9.5±4.5 versus 17.7±5.6;
#CD4+Ki67+FoxP3- (x103); mean±SEM, WT versus Tbx21-/-,
165.7±92.8 versus 106.6±42.7] (Online Supplementary Figure
S2). Furthermore, Tbet deficiency did not alter Treg cell Bcl-
2 expression [#CD4+bcl2+FoxP3+ (x103); mean±SEM, WT
versus Tbx21-/-, 36±4.3 versus 228.1±101.5; mean±SEM,
#CD4+bcl2+FoxP3- (x105); mean±SEM, WT versus Tbx21-/-,
73.9±42.7 versus 70.9±41.5] (Online Supplementary Figure S3).
Therefore, Tbx21−/− Treg cells are similar to WT Treg cells
with respect to their proliferation and apoptotic tendency
during chronic GvHD. 
Tbet restricts CD4+ peripheral T-regulatory-cell 
generation
Tbet cross-regulation of FoxP3 might occur through sev-
eral mechanisms, one of which involves the ability of Tbet
to inhibit FoxP3 expression and subsequent peripheral
Treg generation.34 We considered the possibility that bona
fide effector CD4+ T cells might be more amenable to
FoxP3 expression and acquiring a Treg phenotype in the
absence of Tbet. To elucidate the intrinsic mechanistic
implications of Tbet deficiency in FoxP3 expression, we
determined whether direct Tbet inhibition of FoxP3
occurs. In light of the report by Eckerstorfer et al.,35 we
sought to identify whether Tbet regulates FoxP3 expres-
sion and has binding sites in the evolutionary conserved
region (ECR) upstream of the Foxp3 promoter site. ECR1,
2 and 3 induce Foxp3 promoter activity in human cells by
luciferase assays. In particular, ECR3, which is located in
close proximity to ppp1r3f, enhanced Foxp3 promoter
activity with negligible ppp1r3f activity. Using chromatin
immunoprecipitation sequencing analysis in Th1 polar-
ized cells (GSM836124),36 we determined that Tbet has a
binding site in the ECR3 region upstream of the Foxp3 pro-
moter (Figure 3A). To validate this site, naïve CD4+ T cells
from WT and Tbx21-/- mice were polarized with IL-2,
TGF-β1, IL-12 and IL-18 (Figure 3B) prior to chromatin
immunoprecipitation analysis. Lack of Tbet preferentially
increased Foxp3 expression in induced Treg (iTreg) cells
that were exposed to Th1 cytokines [% CD4+FoxP3+;
mean±SEM, WT versus Tbx21-/-, 21±2.0 versus 45.7±2.2]
(Figure 3C). In contrast, FoxP3 expression in iTreg cells
generated from WT and Tbx21-/- cohorts were 61% versus
59%, respectively. WT iTreg cells cultured with IL-12 and
IL-18 had significant Tbet co-expression with FoxP3 and
enhanced binding to the ECR locus of Foxp3 [%Tbet
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Figure 2. Lack of Tbet alleviates autoimmune graft-versus-host disease. Host BALB/c mice were subjected to total body irradiation (950 cGy) and then reconstituted
with allogeneic B6 T-cell-depleted (TD) bone marrow (BM) (10M) and CD4+ T cells (2M). In certain cohorts, mice were reconstituted with BM and T cells deficient in Tbet.
On day 14 after allogeneic bone marrow transplantation, splenic CD4+ T cells from WT or Tbx21-/- recipients were isolated and adoptively transferred into B6 Rag2−/− mice.
(A) Survival curve after secondary transfer (n=10 per cohort). (B) Representative pictures of colon at day 60 after secondary transfer of WT  (left panel) or Tbx21−/− (right
panel) T cells. (C) Summary of histological scores (n=5 per cohort). Immune cell phenotype was also evaluated at day 60 after secondary transfer. (D) Representative
flow plots showing frequency of IFNγ+ and FoxP3+ T cells in the WT and Tbx21−/− cohorts. (E) Pooled results (n=10 per cohort) for the absolute numbers of splenic CD4+
T cells secreting IFN-γ and (F) absolute number of splenic CD4+ FoxP3+ T cells. (G) Absolute numbers of mesenteric lymph node CD4+ FoxP3+ T cells. (H) Absolute numbers
of CD4+ FoxP3+ T cells from the lamina propria (n=10 per cohort). (I) Absolute numbers of CD4+ FoxP3+ T cells from the skin (n=5 per cohort).
A B
C D
E F G
H I
T-bet restricts FoxP3 
haematologica | 2017; 102(8) 1451
Figure 3. Peripheral Treg numbers are increased in the absence of Tbx21. Chromatin immunoprecipitation (CHIP) sequencing analysis of naïve CD4+ T cells stimulated
for 3 days under Th1 conditions. (A) Peaks denote regions of DNA associated with Tbet binding. The contralateral DNA sequence upstream of the first exon of ppp1r3f is
shown below, with potential Tbet binding sites indicated in blue. (B) Naive CD4+ T cells from WT and Tbx21−/− mice were isolated and polarized under iTreg conditions
[αCD3, αCD28, IL-2 (100 IU) and TGF-β1 (5 ng/mL)] in the presence of rmIL-12 and rmIL-18 (10 ng/mL). On day 3, cells were characterized using intracellular flow cytom-
etry for co-expression of T-bet and FoxP3. (C) Percentage of FoxP3+ iTreg cells in WT and Tbx21-/- mice following stimulation with Th1 conditions. (D) Histograms denote per-
centage of input binding of T-bet to the ECR3 locus upstream of the Foxp3 promoter in WT or Tbx21−/− iTreg polarized in the presence or absence of rmIL-12 and IL-18
measured by CHIP. Data shown are replicates of three experiments. Bone marrow transplantation experiments were carried out with either WT T cells (B6.Foxp3GFP) or T
cells deficient in Tbet (B6.Tbx21-/-Foxp3GFP) to allow flow sorting for FoxP3- T cells for secondary transfer. Splenocytes were harvested 60 days after transplant and then
flow cytometry was performed in unstimulated cells to detect FoxP3 frequency. (E) Representative flow cytometry plot of peripheral Treg induction in WT and KO cohorts.
(F) Pooled analysis of frequency of Treg induction in WT and KO (n=5 per cohort). (G) Absolute numbers of induced Treg cells in WT and KO cohorts during autoimmune
GvHD.
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bound to DNA; WT iTreg versus WT iTreg + Th1
cytokines; 0.015±0.001 versus 0.025±0.002] relative to con-
trol Tbx21-/- iTreg cells (Figure 3C). Allogeneic bone mar-
row transplantation was performed using CD4+ T cells har-
vested from B6.Tbx21-/-FoxP3GFPmice; then, 14 days after
the transplant, effector T cells were purified by flow
cytometry (CD4+GFP-) and transferred into Rag2-/- recipi-
ents. At day 60 after transfer, recipients of Tbet-deficient T
cells were devoid of clinical autoimmune GvHD and had
increased Treg cells [%CD4+FoxP3+, mean±SEM, 1.4±0.3
versus 4.8±0.6; # CD4+FoxP3+ (x104), mean±SEM, 2.1±0.5
versus 8±1.7] (Figure 3E representative data; 3F,G pooled
data). Tbet is, therefore, a critical checkpoint and prevents
peripheral Treg generation during ongoing autoimmune
GvHD. These results stand in contrast to those of studies
showing the importance of Tbet32 or GATA337,38 expression
in FoxP3+ Treg cells. However, there is emerging literature
indicating that this may not be the case in autoimmune
syndromes in which acquisition of Tbet generates dysfunc-
tional Treg cells.39 As such, these data illustrate that Tbet
can bind to the ECR3 locus of the FoxP3 promoter in vitro
and demonstrate that lack of Tbet positively regulates
peripheral Treg generation during chronic GvHD.
Tbet-deficient T-regulatory cells cross-regulate 
pathogenic T cells
Infectious disease models suggest that Treg cells that do
not express Tbet have limited functional capacity.32,40 Such
functional Treg defects have been attributed to homing
defects that occur in the absence of Tbet rather than to a
Treg suppressor defect.41,42 We thus sought to identify
whether Treg cells generated in the absence of Tbet were
functional. Cell mixing studies incorporating congenic
donor cells were performed to evaluate whether induced
peripheral Treg cells from Tbet-deficient CD4+ cells might
inhibit otherwise pathogenic WT CD4 effectors (see
experimental design, Online Supplementary Figure S4A).
Recipients of a 1:1 mix of WT and Tbet-deficient T cells
had decreased CD4+IFNγ+ cells in the WT compartment as
compared to the WT cohort alone [% CD4+IFNγ+,
mean±SEM; WT versus Tbx21-/- versus WT (1:1) versus WT
(1:10) versus Tbx21-/- (1:1) versus Tbx21-/- (1:10); 41.3±2.9 ver-
sus 3.8±0.6 versus 21.4±0.8 versus 28.2±4.1 versus 1.9±0.6
versus 2.5±0.8] (Figure 4A,B). Therefore, Tbet-deficient
Treg cells dampened WT cytokine secretion in vivo thereby
cross-regulating otherwise pathogenic effectors. Also,
although increased FoxP3 frequency was noted in the WT
compartment in the presence of Tbet-deficient cells [%
CD4+FoxP3+, mean±SEM; WT versus Tbx21-/- versus WT
(1:1) versus WT (1:10) versus Tbx21-/- (1:1) versus Tbx21-/-
(1:10); 1.7±0.3 versus 4.2±0.5 versus 4.5±1.1 versus 1.5±0.5
versus 3.7±0.8 versus 1.9±0.8] (Figure 4C,D), this was not
reflected in absolute numbers of FoxP3 cells [#CD4+FoxP3+
(x103), mean±SEM; WT versus Tbx21-/- versus WT (1:1) ver-
sus WT (1:10) versus Tbx21-/- (1:1) versus Tbx21-/- (1:10);
14.4±5 versus 51.9±24 versus 35.8±3.6 versus 17.1±8.8 versus
59.6±23.6 versus 24.7±13.2] (Figure 4E); this result is con-
sistent with a model in which there is a cell-intrinsic regu-
lation of FoxP3 by Tbet. 
Tbet-deficient T-regulatory cells modulate clinical
graft-versus-host disease manifestations in the 
presence of wild-type pathogenic cells
An additional experiment was performed to confirm
Tbet-deficient cell cross-regulation of pathogenic WT
effectors and to further characterize the resultant modula-
tion of chronic GvHD. Consistent with the results shown
in Figure 4, we found that: (i) recipients of WT T cells had
reduced absolute numbers of Treg cells relative to recipi-
ents of non-alloreactive T cells during chronic GvHD; (ii)
recipients of Tbet-deficient alloreactive T cells had
increased Treg cells during the autoimmune phase relative
to recipients of alloreactive WT cells; and (iii) Tbet-defi-
cient T cells cross-regulate pathogenic WT cells, as evi-
denced by increased Treg cells (Figure 5A). Furthermore,
recipients of Tbet-deficient T cells and recipients of the
mix of T-bet deficient and WT T cells had reduced secre-
tion of IFN-γ in response to syngeneic dendritic cells rela-
tive to WT T-cell recipients (Figure 5B). Syngeneic recipi-
ents of WT T cells had increased weight loss at day 17
after transfer (Figure 5C) relative to both recipients of
Tbet-deficient T cells (P=0.0012) and recipients of the 1:1
mix (P=0.0003); however, weight of WT cell recipients
recovered to values similar to that of other cohorts.
Nonetheless, recipients of WT T cells later developed
extensive hair loss, primarily across the back (see photo-
graphs, Online Supplementary Figure S5); the other three
cohorts did not have clinical hair loss. To characterize the
apparent cutaneous autoimmune chronic GvHD, histol-
ogy was performed.  In syngeneic recipients of WT cells,
there was mild acanthosis and mild hyperkeratosis (Figure
5D; stage 1 of 4); in contrast, there was no acanthosis or
hyperkeratosis in syngeneic recipients of Tbet-deficient
cells or recipients of both WT and Tbet-deficient cells.
These results were observed consistently (Figure 5E). The
histological evidence of chronic skin GvHD was observed
in clinically affected and non-affected skin samples in WT
recipients; this latter result indicates that histological evi-
dence of chronic GvHD is a more sensitive parameter than
the clinical sign of hair loss. In this experiment, in which
the clinical presentation was mild relative to that of previ-
ous experiments, we did not observe evidence of intestinal
GvHD by histology. In parallel with histological studies,
we performed RNA quantification of molecules associated
with autoimmunity. As shown in Figure 5F, recipients of
Tbet-deficient cells or the mix of WT plus Tbet-deficient
cells had similar expression of CD4 RNA relative to WT
recipients but had reduced expression of TGF-β1; of note,
TGF-β represents an effector molecule for cutaneous
chronic GvHD.43 In addition, relative to recipients of WT
cells, skin samples from recipients of Tbet-deficient cells
or a mix of Tbet-deficient cells plus WT cells had reduced
RNA expression of inflammatory mediators, including IL-
6 (WT versus KO: P=0.013; WT versusMix: P=0.006), TLR2
(WT versus KO: P=0.004; WT versus Mix: P=0.004), and
TLR7 (WT versus KO: P=0.0006; WT versus Mix:
P=0.0002). These data indicate that Tbet-deficient cells,
even when administered with otherwise pathogenic WT
cells, increase Treg cells and decrease the molecular,
pathological, and clinical features of autoimmune chronic
GvHD.
Discussion
We used alloreactive T-cell transfer into a syngeneic
murine host model to study the autoimmune manifesta-
tions of chronic GvHD. Development of autoimmunity
was dependent on intact Th1 signaling in the transferred
T cells. The ability of the cells to secrete IFN-γ did not
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affect the disease course, and we did not find any differ-
ences in the ability of the cells to proliferate or traffic to
target organs in the absence of IFN-γ signaling. By con-
trast, the absence of IFN-γ signaling and deletion of Tbet
was associated with the generation of peripheral Treg cells
from CD4+ T cells that had been primed in an alloreactive
environment.
By comparing IFN-γ−deficient with IFN-γ signaling-defi-
cient T cells, we dissected the critical role of Th1 signaling
molecules from the less contributory role of the Th1
cytokine IFN-γ. The inflammatory syndrome associated
with alloimmunity and autoimmunity has historically
been attributed to the presence of Th1 and Th17 cells.14,44
Moreover, IFN-γ is pivotal to Treg function during alloim-
munity,45 while Treg cells expressing IFN-γ are dysfunc-
tional in autoimmunity.39 Here, we show that the com-
plete abrogation of Th1 differentiation factors rather than
the absence of the Th1 cytokine IFN-γ reduces autoim-
mune chronic GvHD.
We identified a novel regulatory mechanism by which
Tbet modulates peripheral Treg generation, namely, that
Tbet binds to the ECR3 locus of the Foxp3 promoter.
There is a paucity of data regarding the functionality of
the ECR regions upstream of the Foxp3 promoter. There
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Figure 4. Functional Treg cells are generated in the absence of Tbx21. In co-adoptive
transfer experiments, WT T cells isolated on day 14 after allogeneic bone marrow trans-
plantation were adoptively transferred (0.5M) into B6 Rag2-/- recipients either alone or in
combination with KO T cells at a ratio of 1:1 (WT: Tbx21−/−) or 10:1 (WT: Tbx21−/−). On day
60 after secondary transfer, splenocytes were characterized (n=10 per cohort). (A)
CD4+IFNγ+ cells in WT (i) and Tbx21−/− (ii), WT in the presence of Tbx21−/− (iii) cells at a 1:1
ratio, WT in the presence of Tbx21−/− cells at a 10:1 ratio (v). The bottom middle and right
panels show the percentages of CD4+IFNγ+ cells in the Tbx21−/− fraction after co-existence
with WT cells at a ratio of 1:1 (iv) or 1:10 (vi). (B) Pooled data are shown for CD4+IFNγ+ cell
frequency, (C) FoxP3+ T cells in WT (i) and Tbx21−/− (ii), WT in the presence of Tbx21−/− (iii)
cells at a 1:1 ratio, WT in the presence of Tbx21−/− cells at a 10:1 ratio (v). The bottom mid-
dle and right panels show the percentages of FoxP3+ T cells in the Tbx21−/− fraction after
co-existence with WT cells at a ratio of 1:1 (iv) or 1:10 (vi). (D) Pooled data are shown for
FoxP3+ Treg cell frequency (n=10 per cohort). (E) Pooled data are shown for FoxP3+ Treg
cell number (n=10 per cohort).
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Figure 5. Tbet-deficient cells have reduced chronic graft-versus-host disease potential and modulate otherwise pathogenic WT cell-induced chronic graft-versus-host
disease. WT and Tbet-deficient T cells were isolated on day 14 after allogeneic bone marrow transplantation and adoptively transferred into B6 Rag2-/- recipients either
alone or combined in a ratio of 1:1 (WT:Tbx21-/-). An additional control cohort (“Control”) first received a syngeneic transplant with WT cells followed by a secondary trans-
fer into the syngeneic B6 Rag2-/- host. (A) On day 50 after secondary transfer, recipients were euthanized, and splenic T cells were evaluated by flow cytometry and the
absolute number of CD4+ Foxp3+ cells derived from the WT or Tbx21-/- inoculum was calculated. (B) Post-transfer splenic T cells were also stimulated ex vivo with syn-
geneic dendritic cells and the 24 h supernatant was evaluated for IFN-γ content. (C) After transfer into B6 Rag2-/- hosts, the four cohorts were monitored for weight loss.
(D) On day 50 after syngeneic transfer, recipients were killed and skin samples were evaluated for histological evidence of cutaneous chronic GvHD by hematoxylin and
eosin staining; as illustrated in these representative photomicrographs, there was mild acanthosis and hyperkeratosis in recipients of the WT cells (affected areas indi-
cated by arrows). (E) Cumulative data from the cohorts indicate the consistency of the histology findings; samples in the WT cohort were evaluated from both clinically
affected and non-affected regions of the skin. (F) RNA expression of inflammatory molecules was evaluated in the skin tissues using QuantiGene Plex assay; results for
control CD4 expression and TGF-β1 expression are shown. For these experiments, there were five replicates in the control cohort and seven replicates in the other
cohorts; however, for the RNA studies, there were five replicates in each cohort. Results shown are mean values ± SEM.
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are three highly conserved ECR regions (ECR1, 2 and 3)
which are located upstream of the transcriptional start
site.35 ECR3, which lies proximal to the pppr13f gene, sur-
prisingly, had transcriptional activity in the direction of
FoxP3. While no specific role for ECR3 has been defined
by our experiments, we show for the first time that the
ECR3 region upstream of the Foxp3 gene possesses Tbet
binding sites. The importance of Tbet binding to this locus
is reflected in the in vivo experiments in which lack of Tbet
allowed for the generation of peripheral Treg cells, there-
by abrogating the typical Treg deficiency during chronic
GvHD. Hence both the chromatin immunoprecipitation
and in vivo data are consistent with a model whereby Tbet
possesses a vital regulatory function in FoxP3 expression
in the context of chronic GvHD. 
Tbet is vital for the development of acute GvHD,3 while
its role during chronic GvHD is less clear. Here, for the first
time, Tbet has been shown to be critical not only in the
pathogenesis of chronic GvHD but also in limiting Treg
cells. Indeed, a cumulative increase in Treg cells was noted
in the secondary lymphoid organs and GvHD target tissues
in Tbx21-/- recipients, which correlated with decreased
pathogenesis. Our observations are consistent with previ-
ous reports according to which: (i) Treg cells in chronic
GvHD patients with a favorable prognosis failed to express
Th1 chemokine factors;46 and (ii) expression of the Th1 phe-
notype in Treg cells from patients with multiple sclerosis
was associated with diminished Treg function.39 Our results
elucidate the specific role of Th1 transcription factors in
Treg function during chronic GvHD. Although the presence
of Th1 transcription factors within Treg cells allows these
cells to combat Th1-mediated damage during infectious dis-
ease,32,47 our data suggest  that in protracted autoimmune
disorders such as chronic GvHD, Tbet becomes a negative
regulator of FoxP3 expression in Treg cells.
Co-transfer experiments using WT and Tbx21-/- alloreac-
tive cells confirmed the generation of functional Treg cells
in the absence of Tbet. Such co-adoptive transfer
decreased IFNγ+ T cells in the WT compartment, increased
Treg cells during autoimmune chronic GvHD, and
reduced the molecular, pathological, and clinical evidence
of chronic GvHD. Our experiments also show that the
GvHD autoimmune model that we utilized can result in a
diversity of clinical presentations, the variability of which
is not currently known but may involve factors such as
host microbial status. Tbet-deficient cells, including when
used in combination with otherwise pathogenic WT cells,
had the potential to reduce both manifestations such as
autoimmune colitis and resultant lethality and more pro-
tracted manifestations such as cutaneous chronic GvHD.
We focused on cytokine-mediated events in autoimmune
chronic GvHD, namely the role of IFN-γ, which we found
was relatively non-contributory given the lack of disease
modulation in IFN-γ KO recipients. It should be noted that
cytolytic pathways, namely perforin/granzyme, fas lig-
and, and TNF-α contribute to GvHD, although these path-
ways are less well characterized in chronic GvHD models.
Our experiments did not evaluate the role of these cytolyt-
ic pathways, and as such, it is possible that deficiency in
these pathways might ameliorate autoimmune GvHD and
perhaps likely that Tbet-deficiency would reduce these
cytolytic effector mechanisms for amelioration of disease.
However, the capacity of the Tbet-deficient cells to down-
regulate the otherwise pathogenic WT cells in cell mixing
studies provides evidence for a cross-regulatory mecha-
nism to the Tbet-deficiency finding rather than a more
direct mechanism involving lack of cytotoxic effector mol-
ecule expression.   
We further clarified the immunopathology of autoim-
munity associated with GvHD. Early reports suggested
that both Th1 and Th2 cells have specific roles in causing
acute GvHD and chronic GvHD24 but not until recently
has the immunopathology of chronic GvHD been widely
investigated. The autoimmune manifestations in GvHD
are primarily thought to be of Th1 origin11,14,48,49 with min-
imal involvement of Th17 cells.14,50 Here, we found that
autoimmune chronic GvHD is indeed caused by CD4+
cells of Th1 origin. Our data are also consistent with clin-
ical observations in chronic GvHD patients where poor
prognosis is correlated to decreased Tregs.16,29
In summary, our study identifies a novel molecular
mechanism that controls the T-bet/FoxP3 axis in the con-
text of chronic GvHD. The data presented here suggest
that adoptive Treg cell therapy strategies currently being
pursued to treat chronic GvHD post-BMT may not be
fully effective until methods to control Th1 signaling can
be harnessed. Inhibition of transcriptions factors such as
Tbet and STAT4 represent key molecular targets for the
treatment of autoimmune GvHD. In addition, our work
specifically delineated the IFNγ signaling pathway in pre-
venting autoimmunity. To boost anti-viral responses, an
intact type I IFNγ signaling and STAT1 activation is criti-
cal. The data presented here suggest that by specifically
inhibiting type II IFNγ receptor signaling, one might be
able to augment Treg cells during chronic GvHD while
maintaining type I mediated anti-viral responses. We
envision that use of antagonists against IFNγ type II
receptor might be particularly beneficial for therapy of
autoimmune chronic GvHD. Therefore, the Tbet path-
way, including the IFN-γ receptor and STAT1/STAT4 as
upstream pathway members, drives experimental
autoimmune GvHD. Interventions that restrict the Tbet
pathway might either be used alone or in combination
with adoptive Treg-cell therapy for treatment of autoim-
mune chronic GvHD.   
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